中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
13期
1924-1926
,共3页
直肠肿瘤%放射疗法%药物疗法
直腸腫瘤%放射療法%藥物療法
직장종류%방사요법%약물요법
Rectal neoplasms%Radiotherapy%Drug therapy
目的 探讨序贯与同步放化疗分别治疗直肠癌的临床疗效及毒副作用.方法 选取90例直肠癌患者,根据疾病分期标准分为Ⅱa期21例(Ⅱa组)、Ⅲa期24例(Ⅲa组)、Ⅱb期23例(Ⅱb组)、Ⅲb期22例(Ⅲb组).Ⅱa组和Ⅲa组患者使用序贯放化疗治疗,Ⅱb组和Ⅲb组使用同步放化疗治疗,分别比较患者的临床疗效和毒副反应发生情况.结果 所有患者的1年和3年随访无1例失访及死亡情况.Ⅱa组和Ⅱb组的1年和3年的总生存时间(OS)与无进展生存时间(PFS)差异均无统计学意义(均P＞0.05);Ⅲa组与Ⅲb组的1年OS差异无统计学意义(P＞0.05),1年PFS、3年OS以及3年PFS差异均有统计学意义(x2=3.993、4.224、4.304,均P＜0.05);Ⅱa组+Ⅲa组的毒副反应发生率(28.89％)与Ⅱb组+Ⅲb组的毒副反应发生率(51.11％)差异有统计学意义(x2=4.629,P＜0.05),对于各系统具体的毒副反应发生率差异无统计学意义(P＞0.05).结论 与序贯放化疗相比,在直肠癌的治疗中,同步放化疗能有效延长患者的OS和PFS,虽增加了患者治疗后的毒副反应,但仍在患者可接受范围内,临床上具有更好的应用价值.
目的 探討序貫與同步放化療分彆治療直腸癌的臨床療效及毒副作用.方法 選取90例直腸癌患者,根據疾病分期標準分為Ⅱa期21例(Ⅱa組)、Ⅲa期24例(Ⅲa組)、Ⅱb期23例(Ⅱb組)、Ⅲb期22例(Ⅲb組).Ⅱa組和Ⅲa組患者使用序貫放化療治療,Ⅱb組和Ⅲb組使用同步放化療治療,分彆比較患者的臨床療效和毒副反應髮生情況.結果 所有患者的1年和3年隨訪無1例失訪及死亡情況.Ⅱa組和Ⅱb組的1年和3年的總生存時間(OS)與無進展生存時間(PFS)差異均無統計學意義(均P＞0.05);Ⅲa組與Ⅲb組的1年OS差異無統計學意義(P＞0.05),1年PFS、3年OS以及3年PFS差異均有統計學意義(x2=3.993、4.224、4.304,均P＜0.05);Ⅱa組+Ⅲa組的毒副反應髮生率(28.89％)與Ⅱb組+Ⅲb組的毒副反應髮生率(51.11％)差異有統計學意義(x2=4.629,P＜0.05),對于各繫統具體的毒副反應髮生率差異無統計學意義(P＞0.05).結論 與序貫放化療相比,在直腸癌的治療中,同步放化療能有效延長患者的OS和PFS,雖增加瞭患者治療後的毒副反應,但仍在患者可接受範圍內,臨床上具有更好的應用價值.
목적 탐토서관여동보방화료분별치료직장암적림상료효급독부작용.방법 선취90례직장암환자,근거질병분기표준분위Ⅱa기21례(Ⅱa조)、Ⅲa기24례(Ⅲa조)、Ⅱb기23례(Ⅱb조)、Ⅲb기22례(Ⅲb조).Ⅱa조화Ⅲa조환자사용서관방화료치료,Ⅱb조화Ⅲb조사용동보방화료치료,분별비교환자적림상료효화독부반응발생정황.결과 소유환자적1년화3년수방무1례실방급사망정황.Ⅱa조화Ⅱb조적1년화3년적총생존시간(OS)여무진전생존시간(PFS)차이균무통계학의의(균P＞0.05);Ⅲa조여Ⅲb조적1년OS차이무통계학의의(P＞0.05),1년PFS、3년OS이급3년PFS차이균유통계학의의(x2=3.993、4.224、4.304,균P＜0.05);Ⅱa조+Ⅲa조적독부반응발생솔(28.89％)여Ⅱb조+Ⅲb조적독부반응발생솔(51.11％)차이유통계학의의(x2=4.629,P＜0.05),대우각계통구체적독부반응발생솔차이무통계학의의(P＞0.05).결론 여서관방화료상비,재직장암적치료중,동보방화료능유효연장환자적OS화PFS,수증가료환자치료후적독부반응,단잉재환자가접수범위내,림상상구유경호적응용개치.
Objective To investigate the clinical efficacy and side effects of sequential and concurrent chemoradiation in the treatment of colorectal cancer.Methods 90 patients with colorectal cancer were divided into ⅡAof 21 cases (Ⅱa group),Ⅲa of 24 cases (Ⅲa group),Ⅱb of 23 cases (Ⅱb group),Ⅲb of 22 cases (Ⅲa group) according to the stage of the disease.Group Ⅱa and Ⅲa were treated by sequential chemoradiation therapy,Ⅱb group and Ⅲb group were treated by concurrent chemoradiation therapy.The clinical efficacy and toxicity were observed and compared.Results All patients were followed up at 1 and 3 years,no one lost and died.1-year and 3-year OS and PFS between group Ⅱa and group Ⅱb had no significant differences (P ＞ 0.05).1-year OS had no significant difference between Ⅲa group and Ⅲb group (P ＞ 0.05),1-year PFS,3-year OS and PFS had significant differences (x2 =3.993,4.224,4.304,all P ＜ 0.05).The incidence rate of toxicities between Ⅱa group +Ⅲa group (28.89％) and group Ⅱb+ Ⅲb (51.11％) had significant difference (x2 =4.629,P ＜ 0.05) ; while for each system specific incidence rate of side effects had no significant difference (P ＞ 0.05).Conclusion Compared with sequential chemotherapy in the treatment of colorectal cancer,concurrent chemoradiotherapy can effectively prolong overall survival and progression-free survival time,and can reduce the costs of treating,although increasing the treatment toxicity,but still within the acceptable range of patients,it has better application value in clinical.
